Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of combination of
fluorouracil/folinic acid and liposomal irinotecan(Onivyde) compared with fluoruracil/folinic
acid in patients with metastatic biliary tract cancer which progressed on 1st line
gemcitabine/cisplatin.
Phase:
Phase 2
Details
Lead Sponsor:
Changhoon Yoo
Collaborators:
Chungnam National University Hospital Inje University Kyungpook National University Chilgok Hospital Ulsan University Hospital